

**Diaceutics PLC
 BLOCK LISTING RETURN**

New York, Belfast and London, 7 April 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long term incentive awards.

Name of applicant:		Diaceutics PLC	
Name of scheme:		UK and Global Share Incentive Plan for employees (the "SIP"), the Employee Share Option Plan (the "ESOP") and the Unapproved Share Option Plan (the "USOP") which includes long-term incentive awards.	
Period of return:	From:	7 October 2025	To: 6 April 2026
Balance under scheme from previous return:		1,256,651 Ordinary Shares of £0.002 each	
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		N/A	
Number of securities issued/allotted under schemes during period:		23,588 Ordinary Shares	
Balance under scheme not yet issued/allotted at end of period		1,233,063 Ordinary Shares	
Number and class of securities originally listed and the date of admission		1,500,000 Ordinary Shares on 6 October 2023	
Total number of securities in issue at the end of the period		84,917,283 Ordinary Shares of £0.002 each	
Name of contact:		Nick Roberts	
Telephone number of contact:		As below	

**Enquiries:
 Diaceutics PLC**

Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFLFEISAILIR